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Dynamic Changes of BRCA1 Subnuclear Location
and Phosphorylation State Are Initiated
by DNA Damage
Ralph Scully,* Junjie Chen,* Robert L. Ochs,² and BARD1, both of which form complexes with BRCA1
in vivo (Scully et al., 1997a; Wu et al., 1996; R. Baer,Kathleen Keegan,³ Merl Hoekstra,³
Jean Feunteun,§ and David M. Livingston* personal communication and data presented below).
The BRCA1 gene is widely expressed in developing*The Dana-Farber Cancer Institute
Harvard Medical School embryos, with a marked preference for replicating cells
(Lane et al., 1995; Marquis et al., 1995). It is essentialBoston, Massachusetts 02115
²The Scripps Research Institute for early embryonic proliferation and development (Go-
wen et al., 1996; Hakem et al., 1996; Liu et al., 1996).La Jolla, California 92037
³ICOS Corporation Recently, its full-length product was found to interact,
directly or indirectly, with Rad51, a major participant inBothell, Washington 98021
§Centre National de la Recherche Scientifique eukaryotic double-strand break repair and homologous
recombination (Shinohara et al., 1992; Baumann et al.,Institut Gustave-Roussy
Cedex 94805 Villejuif 1996; Scully et al., 1997a). BRCA1/Rad51 interactions
have been identified in both mitotic and meiotic cellsFrance
(Scully et al., 1997a), where Rad51 contributes to meiotic
recombination (Ashley et al., 1995; Bishop, 1994; Tera-
sawa et al., 1995). These observations imply that BRCA1Summary
and Rad51 communicate physiologically and further
suggest that BRCA1 functions in the maintenance ofBRCA1 localizes to discrete nuclear foci (dots) during
genome integrity.S phase. Hydroxyurea-mediated DNA synthesis arrest
In keeping with these findings, Sharan et al. (1997)of S phase MCF7 cells led to a loss of BRCA1 from
have reported that another familial breast cancer tumorthese structures. Ultraviolet light, mitomycin C, or
suppressor gene product, BRCA2, can interact withgamma irradiation produced a similar effect but with
Rad51, and that murine embryos lacking wild-typeno concurrent arrest of DNA synthesis. BARD1 and
BRCA2 exhibit radiation sensitivity. Collectively, theseRad51, two proteins associated with the BRCA1 dots,
data suggest that loss of functional BRCA1 or BRCA2behaved similarly. Loss of the BRCA1 foci was accom-
are mutagenic events, and, thereby, accelerate neoplas-panied by a specific, dose-dependent change(s) in the
tic transformation. Interestingly, BRCA1 and BARD1state of BRCA1 phosphorylation. Three distinct DNA
each contain a C-terminal ``BRCT'' domain, which isdamaging agents preferentially induced this change
found in many DNA repair and cell cycle checkpointin S phase. The S phase BRCA1 phosphorylation re-
proteins (Bork et al., 1997; Callebaut and Mornon, 1997;sponse to DNA damage occurred in cells lacking, re-
Koonin et al., 1996). The generic function of the BRCTspectively, two DNA damage-sensing protein kinases,
domain is not clear. However, this segment of BRCA1DNA-PK and Atm, implying that neither plays a prime
has both transactivation (Chapman and Verma, 1996;role in this process. Finally, after BRCA1 dot dispersal,
Monteiro et al., 1996) and growth suppressionpropertiesBRCA1, BARD1, and Rad51 accumulated, focally, on
(Humphrey et al., 1997) and may play a part in dockingPCNA1 replication structures, implying an interaction
BRCA1 onto the RNA polymerase II holoenzyme (Scullyof BRCA1/BARD1/Rad51 containing complexes with
et al., 1997b).damaged, replicating DNA. Taken together, the data
Although these observations are consistent with aimply that the BRCA1 S phasefoci are dynamic physio-
role for BRCA1 in DNA repair and the maintenance oflogical elements, responsive to DNA damage, and that
genome stability, there is little evidence that speaks toBRCA1-containing multiprotein complexes participate
a dynamic function of BRCA1 in this regard. Here wein a replication checkpoint response.
report that BRCA1/Rad51/BARD1 containing S phase
nuclear foci are sensitive to the integrity of the genome,Introduction
undergoing a major structural change in the face of
genotoxic insult. This response to DNA damage is ac-BRCA1 is a tumor suppressor gene that maps to human
companied by a specific change in BRCA1 phosphoryla-chromosome 17q 21.3 (Futreal et al., 1994; Hall et al.,
tion and by the relocation of BRCA1, BARD1, and Rad511990; Miki et al., 1994; Neuhausen and Marshall, 1994;
to sites of ``abnormal'' (nonduplex) DNA structure in SSmith et al., 1992). When one copy of BRCA1 is inacti-
phase cells. These findings suggest that BRCA1 partici-vated in the germ line, affected individuals are predis-
pates in an S phase, DNA damage-dependent cell cycleposed to developing breast, ovarian, and other malig-
checkpoint response.nant tumors (reviewed in Feunteun and Lenoir, 1996).
Until recently, there has been little understanding of how
its product operates as a tumor suppressor or in any Results
other capacity.
BRCA1 is an 1863 residue nuclear polypeptide which Disruption of BRCA1 S Phase Nuclear Foci
by DNA Damageappears in discrete, nuclear foci (dots) during S phase
(Chen et al., 1996; Scully et al., 1996, 1997a). These A proportion of BRCA1 is localized to nuclear foci in
S phase cells. These structures were not detected instructures contain at least two other proteins, Rad51
Cell
426
Figure 1. DNA Damage Disperses BRCA1 S Phase Focal Staining
S phase MCF7 cells were treated with DNA damaging agents, as
indicated. Immunostaining for BRCA1 was performed using mAb
MS13. Cells received either no treatment, HU 1 mM, UV 10 Jm22,
or 5000 Rads and were harvested 1 hr later. The arrow indicates a Figure 2. Specific Phosphorylation of BRCA1 following DNA
rare cell in an HU-treated culture which retains some focal staining Damage
for BRCA1.
(A) Cell cycle variation in BRCA1 gel mobility. MCF7 extracts were
immunoblotted for BRCA1 using mAb MS110. Migration of BRCA1
is indicated. Async, asynchronous culture (58% G1, 30% S); starved,
cells after 24 hr of serum starvation (90% G1, 2.5% S); G1, cells 12
hr after release into high serum (86% G1, 7% S); S 1 Nil, cells 24multiple cell lines during G1, when a less intense nucleo-
hr after release into high serum (40% G1, 54% S); S 1 HU, identicallyplasmic BRCA1 immunostaining signal was observed
treated S phase cells (inparallel) cultured after 24 hr of serum refeed-(Scully et al., 1997a). They can be detected using many
ing in HU for 1 hr before harvesting.different BRCA1-specific Abs, raised to distinct epi-
(B) Changes in mobility are due to changes in phosphorylation of
topes, using any of several different fixation methods, BRCA1. BRCA1 IPs were treated with l-phosphatase (see Experi-
or in living cells containing green fluorescent protein mental Procedures) 6 phosphatase inhibitors, as indicated, and
then immunoblotted for BRCA1. IVT, in vitro translated wild-type(GFP)-tagged BRCA1 (Scully et al., 1996; R. S., D. M. L.,
BRCA1. Left panel, MCF7 cells were asynchronous. Right panel,J. A. DeCaprio, and P. A. Silver, unpublished observa-
similar treatment of S phase MCF7 cells 6 HU, as indicated. BRCA1tions). Further, BRCA1 foci exist in mouse fibroblast
species are bracketed.nuclei as shown by immunofluorescence with anti-
(C) Phosphorylation of BRCA1 in S phase after DNA damage. S
murine BRCA1 (X. Wu and D. M. L., unpublished obser- phase MCF7 cells were exposed to the treatments shown for 1
vations). Hence, they are general BRCA1 phenomena. hr prior to harvesting. Cell extracts were then immunoblotted for
BRCA1.Since BRCA1 is suspected of playing a role in genome
(D) Cell cycle analysis on samples from (C). BrdU staining and cellintegrity maintenance, we asked whether the S phase
cycle FACS analysis were performed as described in ExperimentalBRCA1 dots were altered in S phase cells after DNA
Procedures. To quantitate BrdU incorporation in S phase cells, adamage and/or when DNA synthesis is interrupted. Hy-
FACS gate was used to exclude G1 and G2 populations. Under each
droxyurea (HU) was used to induce DNA synthesis arrest panel, the histogram gives the mean BrdU fluorescence intensity of
of S phase cultures of the human breast cancer cell gated (S phase) cells, in arbitrary units. HU-treated S phase cells,
which had arrested DNA synthesis, had a mean BrdU fluorescenceline, MCF7. BRCA1 immunostaining of HU-treated cells,
intensity of 13 in the same experiment.performed with any of three different BRCA1monoclonal
antibodies, revealed overt dispersal of BRCA1 nuclear
foci (Figure 1). Given the likelihood that HU treatment
of S phase cells mimics DNA damage (Allen et al., 1994; (e.g., cell indicated by an arrow in Figure 1). The nature
of these foci is discussed below (Figures 5 and 6 andCarr, 1995; Sanchez et al., 1996; Sun et al., 1996), we
asked whether other DNA damaging agents affect the accompanying text).
integrity of the S phase BRCA1 dots. Treatment with
ultraviolet (UV) irradiation, mitomycin C, or gamma irra- Cell Cycle±Specific Phosphorylation of BRCA1
In an effort to understand the mechanisms governingdiation also led todispersal of the dots within 1 hr (Figure
1 and data not shown). Untreated or mock-treated S the migration of BRCA1 into and out of S phase foci, we
sought biochemical correlates of the different BRCA1phase cells revealed typical BRCA1 dots (Figure 1 and
data not shown). Thus, dispersal of BRCA1 S phase foci nuclear immunofluorescence patterns. Immunoblotting
for p220 BRCA1 in asynchronous MCF7 cells revealedmight represent a cellular response to DNA damage. A
few cells retained BRCA1 foci after HU or UV treatment a doublet (Figure 2A). Each band of the doublet reacted
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with BRCA1 monoclonal antibodies (mAbs), MS13, migration of the S phase BRCA1 band, similar to the
effect of HU treatment (Figure 2C). This effect, coupledMS110, SG11, and AP16 (data not shown and Figure 2B).
Serum-starved MCF7 cells contained reduced levels of with the above noted dispersal of BRCA1 S phase foci
(Figure 1), indicated a similarity between the effect ofBRCA1 (Figure 2A). Cells released into G1 for 12 hr
produced an enrichment of the faster migrating band of these DNA damaging agents and HU. However, in con-
trast to HU-treated cells, the response of S phase cellsthe doublet (Figure 2A). In contrast, 24 hr after release
into high serum, when most cells were in S phase, there to two of these three DNA damaging agents did not
include acute DNA synthesis arrest. Specifically, mito-was a further increase in BRCA1 protein level, repre-
sented primarily by the slower migrating form of the mycin C±treated and gamma-irradiated S phase MCF7
cells showed no impairment of BrdU incorporation com-protein (Figure 2A). Similar observations concerning the
migration of G1 and S phase associated forms of BRCA1 pared with untreated controls, at a time when BRCA1
had already undergone the relevant DNA damage-have been made by Ruffner and Verma (1997).
A parallel culture of S phase MCF7 cells was treated induced phosphorylation (Figures 2C and 2D). UV treat-
ment led to a dose-dependent inhibition of BrdU uptake,with HU for 1 hr. Immunoblotting revealed the presence
of a form of BRCA1 that was not detected in untreated with only a modest impairment of DNA synthesis detect-
able in cells treated with 10 Jm22, but near total DNAcycling cells but which migrated more slowly than the
BRCA1 present in untreated S phase cells (Figure 2A). synthesis arrest seen at 50 Jm22 (Figure 2D and data
not shown). Ten joules per square meter did, however,Thus, endogenous ``p220'' BRCA1 was detectable in
at least three different forms: a rapidly migrating, G1- lead to the supershift of the S phase band, as seen
following treatment with HU, mitomycin, or gamma irra-associated form; a more slowly migrating, S phase form;
and an even more slowly migrating form, noted in HU- diation (Figure 2C).
The finding of continued BrdU incorporation into Streated S phase cells.
Thus, BRCA1 might undergo regulated post-transla- phase cells that had sustained acute DNA damage could
be interpreted as unscheduled DNA synthesis (i.e., re-tional modifications, such as phosphorylation. Consis-
tent with this, phosphatase treatment of BRCA1 immu- pair synthesis) in the context of an arrest of scheduled
DNA synthesis. Although some repair process might benoprecipitates (IPs) altered the gel mobility of BRCA1
(Figure 2B). IPs of BRCA1 from asynchronous MCF7 expected to be occurring at this time (e.g., to permit
resolution of abnormal DNA structures at replicationcells, using the C-terminal mAb, SG11, were aliquoted
into three fractions. The first was treated with l-phos- forks), the data are incompatible with the idea that
scheduled DNA synthesis itself had ceased. First, BrdUphatase in the presence of phosphatase inhibitors; the
second with l-phosphatase in the absence of inhibitors; incorporation during repair synthesis should be much
less efficient than during normal DNA replication (Li etand the thirdwas left untreated. IPswere immunoblotted
using the N-terminal BRCA1 mAb, MS110. Phosphatase al., 1996), whereas near normal DNA synthesis levels
were noted after acute exposure tomitomycin C, gammatreatment in the absence of inhibitors resulted in col-
lapse of the BRCA1 doublet into a single band which irradiation, or 10 Jm22 UV. Second, if the BrdU incorpo-
ration detected were a manifestation of repair synthesiscomigrated with in vitro synthesized, clonal BRCA1 (Fig-
ure 2B). Phosphatase treatment in the presence of inhib- alone, a higher density of DNA lesions should produce a
higher level of BrdU incorporation. However, the reverseitors did not perturb the BRCA1 doublet relative to un-
treated IPs (Figure 2B), ruling out nonspecific effects was true for UV treatment, where increasing doses led
to progressive impairment of BrdU incorporation effi-of the phosphatase preparation. Similarly, phosphatase
treatment of BRCA1 IPs, prepared from HU-treated S ciency. Therefore, 1 hr after treatment with either UV
irradiation (10 Jm22), mitomycin C, or gamma irradiation,phase cells, led to its comigration with the phosphatase-
treated BRCA1 species detected in naive S phase cells scheduled DNA synthesis had not yet ceased. There-
fore, DNA damage-associated BRCA1 phosphorylation(Figure 2B). These results strongly suggest that the dif-
ferential gel mobility of the three forms of BRCA1, noted can occur in S phase cells without arrest of scheduled
DNA synthesis.in G1, S phase, and HU-treated S phase cells, is due to
differential phosphorylation. Although three DNA damaging agents and HU had
disparate effects upon scheduled DNA synthesis, theHU treatment of S phase cells, therefore, led to three
measured events: DNA synthesis arrest, dispersal of feature common to all these treatments is their ability
to induce DNA lesions, rather than their effect on theBRCA1 foci, and phosphorylation of BRCA1. DNA syn-
thesis arrest following brief (2 hr) HU exposure was replication machinery per se. HU treatment might be
predicted to produce, at least transiently, ``abnormal''found to be reversible. Removal of HU after this time
led to the resumption of fullDNA synthesis. Furthermore, (i.e., nonduplex) DNA structures at arrested replication
both the BRCA1 foci and the faster migrating S phase forks. The simplest model to explain these phenomena
BRCA1 band reappeared, while the slower HU-associ- would be one in which ``abnormal'' DNAstructures, gen-
ated band disappeared (data not shown). Therefore, erated in S phase, trigger a signaling cascade, one out-
within the time limits of this experiment, all three effects come of which is specific BRCA1 phosphorylation.
of HU were reversible.
Time Course of the Response to UV IrradiationPhosphorylation of BRCA1 after DNA
These results suggest a relationship between DNA dam-Damage in S Phase without Arrest
age-associated phosphorylation of BRCA1 and dis-of Scheduled DNA Synthesis
persal of the BRCA1 dots. This was explored further,Exposure of S phase MCF7 cells to UV irradiation, mito-
mycin C, or gamma irradiation was found to retard the using UV as the stimulus. The phosphorylation status
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of BRCA1 was followed at 10-min intervals following a
pulse of 10 Jm22, administered to S phase MCF7 cells.
A significant alteration in BRCA1 gel mobility was appar-
ent 20±30 min after treatment (Figure 3A). In a similar
experiment, the time course of dispersal of BRCA1 foci
was followed at 5-min intervals, by scoring, at each
time point, four randomly selected confocal microscopic
fields for the percentage of cells containing BRCA1 foci.
Significant dispersal of BRCA1 foci was not detected
until 25 min after the UV pulse (Figure 3B). Thus, at this
UV dose (and also at higher doses, data not shown),
there was a close temporal correlation between dam-
age-induced phosphorylation of BRCA1 and dispersal
of the BRCA1 foci.
Hydroxyurea, Mitomycin C, and UV
Treatments Preferentially Target
BRCA1 in S Phase
The data, noted above, raise the question of whether
BRCA1 is targeted for phosphorylation by DNA damage
only in S phase. The migration pattern of MCF7 in asyn-
chronous or G1-enriched cells provided a means to ad-
dress this question. We had noted (Figure 2A) that there
is a faster migrating form of p220 BRCA1 enriched in
G1 MCF7cells and detectable in asynchronous cultures.
Asynchronous MCF7 cells were subjected to treatment
Figure 3. Time Course and Cell Cycle Specificity of the BRCA1/with HU, UV, or gamma irradiation. One hour later they
DNA Damage Responsewere harvested and immunoblotted for BRCA1. Consis-
(A) Time course of phosphorylation change after UV irradiation. Stently, HU treatment or low-dose UV (10 Jm22) treatment
phase enriched MCF7 cells were exposed to 10 Jm22 UV light, har-induced the predicted BRCA1 gel shift of the upper
vested at the time points indicated, and immunoblotted for BRCA1.
(S phase correlated) but not the lower (G1 correlated) The shift in BRCA1 migration is seen z20±30 min after UV exposure.
BRCA1 band (data not shown). In contrast, gamma irra- (B) Time course of BRCA1 focus dispersal following UV exposure.
diation (5000 Rads) appeared to displace both forms of In a protocol identical to that employed in A, S phase MCF7 cells
were exposed to 10 Jm22 UV light (filled diamonds), or mock treatedBRCA1. This implied that low-dose UV or HU treatment
(open squares), and were harvested at the time points indicated.might produce phosphorylation of BRCA1 in S phase
Each coverslip was stained for BRCA1, and cells in four randomlybut not in G1.
selected confocal fields were scored for the presence or absence
To test this notion directly, we prepared G1-synchro- of BRCA1 nuclear foci. One hundred and fifteen to 185 cells were
nized MCF7 cells by serum starvation followed by 7 hr scored per time point. Results are presented as the percentage of
of incubation in high serum. These synchronized cells cells scoring positive for BRCA1 foci.
(C) S phase specificity of the BRCA1 damage response. MCF7 cellswere then exposed to HU, UV, mitomycin C, or gamma
were released from serum starvation into G1 for 7 hr. After treatmentirradiation and harvested 1 hr later, while still in G1.
with DNA damaging agents, as shown, cells were harvested 1 hrImmunoblotting for BRCA1 in unperturbed control G1
later (while still in G1) and immunoblotted for BRCA1. Extracts of S
cells revealed the presence of the faster-migrating, G1 phase MCF7 and HU-treated S phase cells were analyzed in parallel
form of BRCA1, albeit at levels lower than in S phase to show the relative migration of the G1, G1/damage, S and
cells (Figure 3C, left panel). Strikingly, neither HU, mito- S/damage forms of BRCA1. Note that HU, mitomycin C, and low-
dose UV treatment (10 Jm22) each failed to shift the G1 form ofmycin C, nor low-dose UV treatment (10 Jm22) led to a
BRCA1 under conditions in which the S phase form had undergonechange in the mobility of the G1 band (Figure 3C, right
damage-induced phosphorylation (compare with Figure 2C).panel). Under identical conditions, the S phase band
(D) BRCA1 gel migration change after ionizing radiation. Asynchro-
shifted (compare Figures 2C and 3C). Higher doses of nously growing MCF7 cells were exposed to metered doses of
UV led to a dose-dependent shift in the G1 form of gamma irradiation, harvested 1 hr later, and then immunoblotted
BRCA1 (Figure 3C) as did gamma irradiation (5000 for BRCA1. The lower (G1) band of BRCA1, indicated with an arrow,
was noted to disappear at 50 Rads, whereas the S phase bandRads).
shifted only at doses above 200 Rads.This preferential S phase targeting of BRCA1for phos-
phorylation, following HU, low dose UV, or mitomycin
C, could be interpreted in two ways. First, the sensor(s)
of abnormal DNA structure, or their subsequent amplifi- gamma irradiation. When asynchronous MCF7 cells
were exposed to a range of doses of gamma irradiation,catory cascades, might operate differently between S
phase and G1. Second, the S phase preference for the emergence of BRCA1 species migrating slower than
the S phase band was apparent only at doses aboveBRCA1 phosphorylation after UV/mitomycin C could be
an attribute of the BRCA1 protein itself, rather than of 200 Rads (Figure 3D). In contrast, exposure to 50 Rads
was sufficient to displace the G1 form of the proteinthe signals impinging on it. A hint that the former might
be correct came from examination of the response to (Figure 3D). Therefore, gamma irradiation appeared to
Phosphorylation of BRCA1 after DNA Damage
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shown). Immunoblotting of whole cell extracts was used
to confirm the expression of p460 DNA-PK in MO59K
cells and its absence from MO59J cells (Figure 4A).
BRCA1 phosphorylation after HU or UV treatment was
also detected in both cell lines, and the response to
each of these stimuli was indistinguishable between
MO59J and MO59K cells (data not shown). These results
exclude p460 DNA-PK as a necessary component of
the DNA damage-BRCA1 phosphorylation pathway.
To investigate a potential role for Atm, we analyzed
primary culturesof Atm homozygous mutant fibroblasts.
Both HU and UV exposure elicited a clear retardation
in the migration of the S phase BRCA1 band (Figure 4B).
A similar response to gamma irradiation was also noted
(data not shown), although a quantitative effect of Atm
on the DNA damage-BRCA1 signaling pathway has not
yet been ruled out.
Recruitment of BRCA1 to PCNA- and DNA-
Containing Nuclear Structures after
DNA Damage in S Phase
Close examination of the BRCA1 immunostaining pat-
Figure 4. BRCA1 Damage Response in DNA-PK and ATM Mutant tern after HU treatment or UV irradiation revealed that
Cell Lines the frequency of cells, within S phase cultures, contain-
(A) Asynchronously growing human glioma cell lines, MO59J (DNA- ing BRCA1 nuclear foci, although substantially reduced,
PK null) and MO59K (DNA-PK wild type) were exposed to 5000 was not zero (Figures 1 and 3B). In a small proportion of
Rads, or mock treated, and harvested 1 hr later. Immunoblotting
cells, there were characteristic small, punctate BRCA1for BRCA1 is shown in the left panel, and for DNA-PK in the right
dots. In yet others, a qualitatively different BRCA1 focalpanel.
pattern was detected (see below). The reasons for the(B) Response of AT fibroblasts to HU and UV treatment. Asynchro-
nous cultures of the AT primary human diploid fibroblast culture, presence of these different BRCA1 focal staining pat-
GM02052B, were exposed to DNA damaging agents as shown, har- terns became clear when cells were double stained for
vested 1 hr later, and immunoblotted for BRCA1. BRCA1 and proliferating cell nuclear antigen (PCNA), as
detailed below.
Under some fixation conditions, PCNA immunostain-provide an exception to the above-noted preference for
S phase in signaling from DNA damage to BRCA1. This ing is seen only in cells synthesizing DNA, and given
that its staining pattern changes during S phase, it cansuggests that cell cycle specificity in the BRCA1 DNA
damage response is a property of the particular sensors be used as an S phase temporal marker (Bravo, 1986;
Bravo and Macdonald-Bravo, 1987). In early/mid±Sof and signaling arising from DNA damage, rather than
of the BRCA1 protein itself. phase cells, PCNA immunostaining is in a multifocal/
diffusely nuclear pattern. In late S phase, the staining
pattern changes dramatically and becomes ``nodular.''DNA-Dependent Protein Kinase and the Ataxia
Telangiectasia Gene Product Are Not Required Importantly, throughout S phase, the immunostaining
pattern of BrdU incorporation into replication forksfor DNA Damage-Induced BRCA1
Phosphorylation in S Phase clearly overlies the PCNA stain (Bravo and Macdonald-
Bravo, 1987; Nakamura et al., 1986; Figure 5A). We con-Genetic and biochemical approaches suggest a role for
the PIK family of nuclear protein kinases in linking the firmed, by the use of a mimosine block and release
protocol, that these changes in PCNA morphology aredetection of DNA damage to cell cycle responses (Bent-
ley et al., 1996; Cimprich et al., 1996; Hari et al., 1995; similarly correlated with the stage of S phase in MCF7
cells (data not shown).Hartley et al., 1995; Keith and Schreiber, 1995; Morrow
et al., 1995; Savitsky et al., 1995). This family of proteins In synchronized cells, BRCA1 foci first appear in S
phase. This raised the question of whether BRCA1 fociincludes thecatalytic subunit of DNA-dependent protein
kinase (p460 DNA-PK), Atm, and Atr. Initially, we asked coincide with PCNA foci. This was addressed using two-
color immunostaining followed by confocal microscopy.whether a functional copy of DNA-PK was necessary for
detection of the BRCA1 DNA damage-phosphorylation Images in Figure 5B depict unperturbed, S phase MCF7
cells doubly stained for BRCA1 (green, fluorescein iso-response. The human glioma cell line, MO59, has two
derivatives, one of which (MO59K) is wild-type for p460 thiocyanate [FITC]) and PCNA (red, rhodamine). In re-
peated experiments, the two immunostaining patternsDNA-PK. The other (MO59J) does not express its gene
(Lees-Miller et al., 1995). Using gamma irradiation as the were found to be distinct, even when the PCNA pattern
resembled the nodular one reported for late S phasestimulus, we asked whether the two cell lines could each
respond to DNA damage by phosphorylating BRCA1. cells (Bravo and Macdonald-Bravo, 1987; Nakamura et
al., 1986). Thus, in conventionally cycling S phase cells,Indeed, the two cell lines mounted indistinguishable re-
sponses to gamma irradiation (Figure 4A and data not there was no immunocytochemical indication that
Cell
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Figure 5. Recruitment of BRCA1 to Replica-
tion Structures after HU or UV Treatment
(A) In S phase cells, PCNA immunostaining
can be used to locate sites of DNA synthesis.
Panels depict S phase MCF7 cells, pulsed
with BrdU prior to fixation, double stained
with anti-BrdU mAb (green), and anti-PCNA
Ab (``AK'' serum, red). Where colocalization
of the two images is seen, the signal appears
in the right hand panel as a yellow signal.
(B) Recruitment of BRCA1 to replication
structures after HU treatment. In untreated S
phase cells (``HU2''), BRCA1 foci (mAb
MS13, green) were not significantly coinci-
dent with PCNA (AK Ab, red) in either early S
phase (upper row) or late S phase (second
row). In contrast, in HU-treated cells (``HU1,''
third row), BRCA1 colocalizes extensively
with PCNA in late S phase nuclei, as shown
by the yellow overlap signal of green and red.
Similar results were obtained in UV treated
cells (``UV1,'' lowest row). The arrow points
to a cell carrying BRCA1 dots and no PCNA
staining. This may be a G2 cell.
BRCA1 focally accumulates at replication forks. Further, HU or UV treatment of S phase cells. By contrast, the
small subset of nuclei scoring positive for BRCA1 dotsa small proportion of cells was noted to be positive for
BRCA1 foci and negative for PCNA. This population was but negative for PCNA (presumed G2 cells, as noted
above) were not perturbed by either HU or UV treatmentfound to be enriched in late S phase cultures (data not
shown), suggesting that the presence of BRCA1 foci is (e.g., ``UV1'' panel in Figure 5B, cell indicated by an
arrow).also a feature of some G2 cells.
In contrast, when HU- or UV-treated S phase cultures
were similarly examined, a striking colocalization of the Colocalization of BRCA1, BARD1, and Rad51
before and after DNA Damage in S PhaseBRCA1 staining pattern and the PCNA staining pattern
was noted in those rare, late S phase cells inwhich PCNA Two proteins associated with BRCA1 in S phase fociÐ
Rad51 and BARD1Ðwere examined during the DNAimmunostaining was clearly nodular or focal (Figure 5B
and data not shown). In the majority of S phase nuclei, damage response. Consistent with the described physi-
cal interaction between BRCA1 and BARD1 (Wu et al.,where the PCNA pattern was diffuse, the BRCA1 stain
was also diffuse (data not shown). The overt relocation 1996), BARD1 immunostaining, reflected by binding of
multiple antibodies to BARD1, colocalized with BRCA1of BRCA1 to PCNA1 structures after DNA damage sug-
gests that BRCA1 is recruited to replication forks after in S phase nuclear dots (Figure 6A). This result was
Phosphorylation of BRCA1 after DNA Damage
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Figure 6. Recruitment of BARD1 and Rad51
to Replication Structures after DNA damage
(A) Colocalization of BRCA1 and BARD1 in S
phase nuclear foci. Untreated S phase MCF7
cells, stained with BRCA1 mAb MS13 (green,
FITC) and BARD1 Ab (rhodamine, red). Where
the two nuclear dot signals overlap, a yellow
signal was detected.
(B) Recruitment of BARD1 to replication
structures after HU treatment. The upper
panel depicts untreated S phase MCF7 cells
(``HU2'') double stained for BARD1 (using af-
finity purified polyclonal antiserum to BARD1,
red) and PCNA (using mAb PC10, green). No
significant colocalization of the green and red
signals was noted. The lower panel shows
the same, two-color immunstaining experi-
ment, performed on HU-treated MCF7 cells
(``HU1''). Where BARD1 and PCNA signals
overlap, a yellow color was noted in the right-
hand panel.
(C) Recruitment of Rad51 to replication struc-
tures after HU treatment. Similar treatments
as for (B). Cells were double stained for
Rad51 (using affinity purified polyclonal anti-
serum to Rad51, green) and PCNA (using
``AK'' antiserum, red), as described in Ex-
perimental Procedures. After HU treatment
(``HU1''), but not in untreated cells (``HU2''),
significant colocalization of Rad51 and PCNA
is seen as a yellow overlap.
first obtained by Richard Baer and coworkers (personal the BARD1/Rad51 G2 foci were not perturbed by either
UV or HU treatment (data not shown).communication). S phase (PCNA1) nuclei were exam-
These findings strengthen the notion that BRCA1 relo-ined for BARD1 and Rad51 before and after HU or UV
calizes to replication forks after DNA damage, since ittreatment. As was noted for BRCA1, undamaged cells
does so in the company of two known physiologicalrevealed no significant colocalization of either Rad51 or
partners. Hence, either multiprotein BRCA1-containingBARD1 with PCNA (Figures 6B and 6C, see HU2). After
complexes leave the dots after DNA damage, or theHU or UV exposure, however, colocalization was seen
underlying subnuclear structure which constitutes theon PCNA nodules (Figures 6B and 6C, see HU1). In the
substance of the S phase foci, itself, undergoes disas-majority of S phase nuclei, where the PCNA stain was
sembly after DNA damage.diffuse, Rad51 and BARD1 stains were also found to
have become diffuse (data not shown). Thus, BRCA1
and two known associated proteins, BARD1 and Rad51, Discussion
both concentrate in PCNA-containing, replicating struc-
tures after DNA damage. Like BRCA1 dots, BARD1 and These experiments identify the p220 BRCA1 protein as
Rad51 foci appeared to persist into G2 (data not shown). a participant in a DNA damage response of cycling cells,
thereby fulfilling the prediction that BRCA1 participatesIn addition, as was noted above for BRCA1 foci in G2,
Cell
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in the maintenance of genome integrity (Scully et al., and Young, 1980; reviewed in Elledge, 1996). The yeast
homologs of Atr, rad3sp, and MEC1sc, have been clearly1997a). Within 1 hr of treatment of cells with various
DNA damaging agents, two effects were noted in the implicated in S phase and other DNA damage check-
points (Bentley et al., 1996; Paulovich and Hartwell,behavior of the BRCA1 protein. First, S phase cells lost
the characteristic BRCA1 nuclear foci. Second, the pro- 1995). DNA-PK functions in double-stranded break re-
pair and VDJ recombination (reviewed in Lieber et al.,tein underwent a specific change(s) in phosphorylation.
Third, BRCA1 was now associated with PCNA/replicat- 1997). In addition, the products of these genes are pro-
tein kinases and they interact with yet other proteining DNA-containing structures. The timing of these
events was closely correlated, suggesting that they are kinases. This combined evidence suggests that the
``PIK'' kinases are signal transducers, e.g., linking DNAdifferent manifestations of the same cellular response.
Taken together, these findings allow one to construct a damage with cell cycle events (reviewed in Elledge,
1996). Our observations on BRCA1 suggest that itsfunctional model of BRCA1 behavior, at least during S
phase. phosphorylation after DNA damage might be an assay
for the activity of one or more ``PIK'' kinases. There areFirst, the BRCA1 dots, which clearly contain BRCA1-
containing complexes, given the colocalization of both data in the literature consistent with a model in which
BRCA1 and Atr and, possibly, Atm interact on meioticRad51 and BARD1, appear to be dynamic physiological
structures. Their integrity is, at a minimum, tied to the chromosomes (Keegan et al., 1996; Scully et al., 1997a).
The availability of tissue from ataxia-telangiectasiaintegrity of the genome. DNA damage leads to signals,
transmitted over a measurable period of time, which patients has provided cultured primary cells lacking Atm
function. For each modality of DNA damage exam-result in the loss of BRCA1 containing protein/protein
complexes from these structures, if not the loss of the inedÐHU treatment, UV, or ionizing radiationÐS phase
BRCA1 mobility slowed within 1 hr of exposure. Thus,structures themselves. These signals do not depend
upon the cessation of DNA synthesis for accurate trans- Atm is not absolutely required for S phase DNA damage-
induced phosphorylation of BRCA1. Whether the samemission and are, hence, not a specific result of replica-
tion arrest. Whether the dots are active in the absence is true for G1 cells is unclear at present. Similarly, p460
DNA-PK deficient cells responded normally to this sameof genome damage, playing an as yet unknown role in
the replication process (and/or in postreplication events) spectrum of DNA damaging agents. This implies that
DNA-PK is not an absolute requirement for the S phaseor whether they are simply repositories of proteins that
are active in the damage (and possibly other stress) effect as well. The components of the S phase DNA
damage/BRCA1 signaling pathway, therefore, remain toresponse(s) is not clear. That BRCA1 appears to dis-
perse from the dots after genome damage strongly sug- be identified. Based upon what is known from analyses
of Drosophila and yeast, Atr must be considered a po-gests that BRCA1 itself plays a role in the response to
DNA damage. Such a conclusion strongly supports the tential participant in this pathway. At present, however,
there are no cell lines known to be functionally null forearlier speculation put forward on the occasion of the
first detection of BRCA1/Rad 51 complexes (Scully et Atr.
Finally, BRCA1 appears to relocalize to replicatingal., 1997a). Thus, the BRCA1/Rad51/BARD1 nuclear
dots are an example of multiprotein-containing nuclear DNA structures after DNA damage. The interpretation
of these observations can only be speculated upon atstructures whose integrity is modified by modifiers of
genome integrity. present. HU and UV induced the same relocalization
behavior in BRCA1 (also in Rad51 and BARD1), againSecond, in parallel with the loss of the BRCA1 dots,
DNA damage led to a specific alteration in the state of suggesting that the responses provoked by these two
agents have fundamental similarities. One interpretationBRCA1 phosphorylation. The timing of the two events
was similar, and both events were reversible in HU- of these phenomena is that, in each case, a DNA repair
process is initiated at the replication fork. In the casetreated cells, implying that they are linked and that both
are reflections of the existence of unrepaired DNA dam- of UV-induced damage, DNA replication may be accom-
panied by a recombinational DNA damage responseage. These findings indicate that BRCA1 is a substrate
of one or more kinases activated specifically by DNA (Fornace, 1983; Friedberg et al., 1995). In the case of
HU treatment, the replication fork likely contains a highdamage. They, therefore, place BRCA1 on an S phase
DNA damage-initiated signaling pathway. G1 cells were density of ``abnormal,'' or nonduplex, DNA structures,
which might provoke a DNA damage response. If suchable to respond with specific BRCA1 phosphorylation
events following DNA damage, but there were clear dif- speculations hold true, one might deduce that BRCA1
has an affinity for sites of specialized DNA structure,ferences in the substance of the responses between G1
and S phase cells. Whether the protein contributes to the a conclusion supported by its localization to the axial
element of the developing synaptonemal complexenaction of both G1 and S (and possibly G2) checkpoint
responses remains to be seen. (Kleckner, 1996; Scully et al., 1997a).
If BRCA1 is recruited to certain abnormal DNA struc-One class of genes implicated in such signaling path-
ways encode the ``PIK'' kinases, Atm, Atr, and p460 tures as part of a DNA damage response, a role for
BRCA1 in DNA repair seems likely. This might or mightDNA-PK, each of which shows extensive conservation
between yeast, drosophila and human (Bentley et al., not be linked to an inferred role of BRCA1 in transcription
regulation, as evidenced by its transactivation domain1996; Cimprich et al., 1996; Hari et al., 1995; Hartley et
al., 1995; Keith and Schreiber, 1995; Morrow et al., 1995; and by its stable association with the RNA polymerase
II holoenzyme (Scully et al., 1997b). Two paradigms,Savitsky et al., 1995). Genetic analysis has suggested
a role for Atm in multiple cell cycle checkpoints (Painter which are not mutually exclusive, could be considered.
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(Amersham). IP of BRCA1 was performed as described previouslyFirst, BRCA1 may play a DNA repair role, even in the
(Scully et al., 1997a).context of the RNA polymerase II holoenzyme, perhaps
analogous to some components of TFIIH (reviewed in
Phosphatase Treatment of Immunoprecipitates
Bhatia et al., 1996). Second, BRCA1 may be truly bifunc- BRCA1 IPs were washed in extraction buffer in the absence of
tional (or multifunctional), serving as both a factor in phosphatase inhibitors. Parallel samples were resuspended in
l-phosphatase buffer (New England Biolabs) either in the presencethe processing of abnormal DNA structures and as a
or absence of the phosphatase inhibitors, NaF (50 mM final concen-participant in the signalingwhich results in the activation
tration) and sodium orthovanadate (2 mM final concentration). Afterof certain genes which follow DNA damage. The p53
heating samples to 308C for 1 min, 500 U of l-phosphatase (Newtumor suppressor protein likely operates in such a bi-
England Biolabs) was added to each sample, followed by incubation
functional manner (reviewed in Ko and Prives, 1996). at 308C for 1 hr. Samples were separated by SDS-PAGE and immu-
How do these observations reflect upon the function noblotted for BRCA1. In the same experiments, in vitro translation
of the BRCA1 cDNA was performed using a TNT kit (Promega).of the BRCA1dots in undamagedcells? One might spec-
ulate that the BRCA1 S/G2 phase dots are sites special-
Antibodies, Immunostaining, and Confocal Microscopyized for the processing of replicating or replicated DNA.
Cells were fixed for 10 min in PBS-buffered 3% paraformalde-
It is worth noting, at this point, that BRCA1 is active hyde/2% sucrose solution, followed by 5 min permeablization on
during both the mitotic and meiotic cell cycle and inter- ice in Triton buffer (0.5% Triton X-100 in 20 mM HEPES, pH 7.4, 50
acts with developing synaptonemal complexes (Scully mM NaCl, 3 mM MgCl, 300 mM sucrose). Alternatively, to visualize
replication forks using PCNA Ab, methanol acetone (70%:30% v/v)et al., 1997a). Given the functional parallel between mei-
fixation for 15 min at 2208C was performed. The latter coverslipsotic interhomolog and mitotic intersister interactions
were air dried and rehydrated in PBS prior to immunostaining. Meth-(Kleckner, 1996), one wonders whether function in the
anol/acetone fixation produced poor results with the Rad51 Ab. To
BRCA1 dots is connected with intersister interactions. visualize replication forks in this case, cells were permeablized in
Similarly obscure at present is the relationship that Triton buffer (above) prior to paraformaldehyde fixation, to elute
away the soluble PCNA fraction (a modification of Li et al., 1996).might exist between the mechanisms governing the be-
BRCA1 was visualized using mAbs- MS13, MS110, or AP16 (Scullyhavior of BRCA1 in a replication checkpoint pathway
et al., 1996). PCNA was visualized using AK antiserum at 1:5000, orand the tissue specificity of its role in tumor suppression.
with PCNA mAb PC10 (Santa Cruz) at 1:100. BARD1 was visualized
The connection may become clearer from a better un- using an affinity-purified rabbit polyclonal antiserum to residues
derstanding of the biology of breast and ovarian epi- 141±388 of the gene product. This was shown to colocalize with
thelium. BARD1-specific mAbs, confirming the identity of the signal. Cross-
reactivity between this antiserum and BRCA1 protein was sought
but not detected. Rad51 Ab was generated by immunization of
Experimental Procedures rabbits with GST-Rad51 fusion protein. After absorption of anti-GST
Abs, affinity purification was performed by standard methods using
Tissue Culture Methods an aminolink column (Pierce) coupled to GST-Rad51. All secondary
Cells were cultured in Dulbecco's modified Eagle's medium antibodies used were species-specific fluorochrome-conjugated
(DMEM)±10% fetal bovine serum (FBS). MCF7 cells were synchro- Abs from Jackson Immunoresearch, used at 1:200 throughout.
nized as described previously (Scully et al., 1997a). For late G1 Two-color immunostaining for BrdU and PCNA was performed
synchronization, mimosine (200 mM final concentration) was added as follows. Methanol-acetone fixed cells were stained with PCNA
to MCF7 cells for 16 hr. Release into S phase produced tight syn- antiserum ``AK'' (from R. Ochs), followed by secondary Ab. After
chrony through this segment of the cycle, allowing preparation of post-fixing in paraformaldehyde/sucrose solution (above) for 10 min
early or late S phase cultures. at room temperature, cells were incubated for 5 min in 2 N HCl to
expose incorporated BrdU. After multiple phosphate-buffered saline
(PBS) washes, fluorescein isothiocyanate (FITC)-conjugated anti-DNA Damaging Agents
BrdU mAb (Becton Dickenson) was used to develop a BrdU incorpo-Cells were exposed to genotoxic agents and, unless otherwise
ration signal.stated, harvested 1 hr later. HU (Sigma) treatment was added to a
All antibody incubations were performed at 378C for 20 min. Underfinal concentration of 1 mM. Mitomycin C (Sigma) was added to a
the conditions used, no significant signal attributable to secondaryfinal concentration of 20 mg/ml. UV doses were delivered in a single
antibody, alone, was detected. All images were collected by confo-pulse using a Stratalinker (Stratagene). Prior to pulsing, medium
cal microscopy (Zeiss) and processed using Adobe Photoshopwas removed, being replaced immediately after treatment. Gamma
software.irradiation was delivered using a Gammacell 1000 apparatus.
Cell Cycle Analysis
Immunoblotting and Immunoprecipitation of BRCA1 Cells were pulsed with BrdU (Boehringer-Mannheim) for 10 min
Cell extracts were prepared in EBC buffer (50 mM Tris, pH 8, 120 prior to harvesting. Aliquots of harvested plates were trypsinized,
mM NaCl, 0.5% Nonidet P-40 [NP-40]), with the addition of 50 mM neutralized, washed in PBS, and fixed in cold 70% ethanol while
NaF, 1 mM sodium orthovanadate, 100 mg/ml polymethylsulfonyl vortexing. After storage on ice, cells were vortexed into 2 N HCl/
fluoride (PMSF), 20 mg/ml aprotinin, and 10 mg/ml leupeptin. One 0.5% Tween-20. After 30 min of incubation, cells were washed twice
hundred micrograms of whole cell extract were loaded per lane. To in PBS/HEPES, pH 7.4, to restore physiological pH, and incubated
detect changes in the mobility of p220 BRCA1, prolonged 5 or 6% with 50 ml of PBS/1% BSA/0.5% Tween-20 and 20 ml of FITC-conju-
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used gated anti-BrdU mAb (Becton-Dickenson), for 30 min at room tem-
(e.g., 100 V for 16 hr). Transfer to nitrocellulose was performed using perature. After further washes, cells were incubated in 70 mM propi-
a semidry transfer method (Novablot, Pharmacia), in 50 mM Tris dium diiodide dissolved in 38 mM sodium citrate, in the presence
base, 40 mM glycine, 0.37 g/l SDS, 20% methanol (for 3 hr at 1.5 of DNAase-free RNAase (2.5 mg/ml final concentration, Boehringer-
mA/cm2). After blocking with 5% nonfat dried milk in TBS-T (20 mM Mannheim) for 30 min at 378C. Samples were analyzed immediately
Tris, pH 8, 0.9% NaCl, 0.05% Tween 20) with sodium azide (0.1%), thereafter by FACS (Becton-Dickenson).
the primary antibody,MS110 (Scully et al., 1996; OncogeneScience),
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